Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Randomised, Double-blind, Placebo-controlled Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD)
Authors not listed
PRInnovation GmbH · 2024
Abstract
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour. The company PRInnovation is developing a new treatment for Alzheimer's disease, called PRI-002. It is thought that PRI-002 can cut the sticked substances back into small pieces. That would reduce the effects of Alzheimer's disease. In the current study the investigators examine whether PRI-002 is safe and effective in participants with mild cognitive impairment (MCI) or mild dementia due to AD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2024). Randomised, Double-blind, Placebo-controlled Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD). <em>PRInnovation GmbH</em>. https://clinicaltrials.gov/study/NCT06182085
Vancouver
Anonymous. Randomised, Double-blind, Placebo-controlled Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD). PRInnovation GmbH. 2024.
BibTeX
@misc{anon2024Random,
title = {Randomised, Double-blind, Placebo-controlled Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD)},
author = {Anonymous},
journal = {PRInnovation GmbH},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell Death and Differentiation 2008
Citation only
Astroglia in dementia and Alzheimer's disease
Icahn School of Medicine at Mount Sinai 2019
Open access · US-GOV
Light, Metabolic Syndrome and Alzheimer's Disease: A Non-Pharmocological Approach
AstraZeneca 2016
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Flint Rehabilitation Devices, LLC 2023
Open access · US-GOV
FitMi AD: a Safe and Motivating Computer-guided Exercise System for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease
University of California, San Francisco 2021
Open access · US-GOV
Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease
The Lancet 2021
Preprint · OA